Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

This study is a prospective, open-label, randomized controlled trial that enrolled previously untreated patients with locally advanced or metastatic pancreatic cancer. Participants were randomly assigned to receive either albumin-bound paclitaxel and gemcitabine, or albumin-bound paclitaxel, gemcitabine, and S-1 as first-line treatment. After patients who met the inclusion criteria signed an informed consent form, the study observed patients from the start of treatment until death, withdrawal of consent, loss to follow-up, or the end of the study. Eligible participants were randomly assigned i

Trial Details

NCT ID
NCT06789679
Phase
PHASE2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Gemcitabine, albumin-bound paclitaxel, S-1
  • Gemcitabine, albumin-bound paclitaxel
Locations (sample)
  • Beijing, Chaoyang District, China|39.9075,116.39723

Key Eligibility Criteria

  • The participant must voluntarily agree to participate in the study and sign the informed consent form.
  • The participant must be ≥18 years old on the day of signing the informed consent form.
  • The participant must have a pathological diagnosis of pancreatic ductal adenocarcinoma (including adenosquamous carcinoma).
  • The participant must not have received any prior systemic treatment for unresectable locally advanced or metastatic pancreatic cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →